Category Archives: Genome

PBR Staff Writer Published 16 March 2015

German drug discovery firm Evotec and US-based biotechnology company Second Genome have entered into a partnership for small molecule-based discovery and development activities to treat microbiome-mediated diseases.

The deal, which triggers an undisclosed upfront payment, includes the discovery and optimisation of new compounds as well as licence agreements for already existing assets developed by Evotec.

Under the deal, Second Genome's approach to identify and modulate microbiome-mediated pathways will be further improved by the use and results of Evotec's integrated drug discovery platform.

Both the firms will jointly work to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities.

Evotec chief scientific officer Dr Cord Dohrmann said: "We are pleased to contribute to Second Genome's unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut.

"The enrichment and maturation of Second Genome's project portfolio through our contributions will enhance the Company's clinical pipeline in the near future."

As part of the collaboration, Evotec is also eligible for pre-clinical, clinical, regulatory milestones and royalty payments related to commercialisation.

Second Genome chief business officer Mohan Iyer said: "The partnership with Evotec allows us efficiently to translate our unique microbiome discovery platform efficiently into tangible drug molecules for clinical development.

"Our enriched pipeline offers new treatment approaches for patients across a wide range of diseases with an initial focus on inflammatory conditions. We look forward to a sustained partnership with Evotec."

View post:
Evotec, Second Genome to discover new treatment for microbiome-mediated diseases

Life science researchers at Virginia Tech have accelerated a game-changing technology that's being used to study one of the planet's most lethal disease-carrying animals.

Writing in this week's Proceedings of the National Academy of Sciences, researchers revealed an improved way to study genes in mosquitoes using a genome-editing method known as CRISPR-Cas9, which exploded onto the life science scene in 2012.

Editing the genome of an organism allows scientists to study it by deleting certain genes to observe how the organism is affected, or even to add new genes. The new technique makes the editing process more efficient and may accelerate efforts to develop novel mosquito-control or disease-prevention strategies.

"We've cut the human capital it takes to evaluate genes in disease-carrying mosquitoes by a factor of 10," said Zach N. Adelman, an associate professor of entomology in the College of Agriculture and Life Sciences and a member of the Fralin Life Science Institute. "Not a lot of research groups have the resources to spend four months working with up to 5,000 mosquito embryos to investigate a gene that may ultimately have no bearing on their work. Now they can potentially do the same investigation in a week."

Mosquitoes transmit pathogens that cause malaria, dengue fever, and other high-impact diseases. In 2013, Malaria killed an estimated 584,000 people, most of them young children, according to the World Health Organization. Bill Gates, the co-founder of Microsoft and a philanthropist who supports social and health causes, has called the mosquito the world's deadliest animal.

"The mosquito is incredibly important as far as transmission of disease," said Kevin M. Myles, an associate professor of entomology in the College of Agriculture and Life Sciences and a member of the Fralin Life Science Institute. "With this model, any scientist asking a question about a mosquito phenotype can now find its genetic cause. That's important for basic research into mosquito biology and applied research to control disease-vector mosquitoes."

The scientific community has long rallied to fight mosquito-borne diseases.

"I am excited by the paper," said Laura C. Harrington, professor and chair of entomology at Cornell University, who was not involved in the research. "We are desperately in need of faster and more efficient ways to transform mosquitoes. This single hurdle is holding the entire field back from making the discoveries that will lead to novel and effective approaches to mosquito and, consequently, disease control."

When CRISPR arrived in 2012, it drastically reduced the time it took for researchers to rewrite an organism's DNA.

Medical and life scientists quickly saw the technique's potential to edit disease-causing genes in people or, in the case of mosquito research, strategically modify the genome of an animal known to carry parasites and viruses that cause malaria, dengue fever, and other high-impact diseases.

Here is the original post:
Life scientists streamline cutting-edge technique to edit mosquito genome

Subaru Impreza STI Genome exhaust sound
Subaru Impreza MY06 Hawkeye FIX NON Turbo - N/A Impreza Exhaust - Muffler - Auspuff - Sportauspuff Subaru Impreza STI Genome Exhaust sound. Not WRX STI Subar...

By: east alps custom

Read the original:
Subaru Impreza STI Genome exhaust sound - Video

MBT716 Lecture 6: Genome Browsers
This channel offers lectures and educational materials in Arabic about bioinformatics. The materials are provided by Dr. Yaqoub Ashhab from the Biotechnology...

By: Bioinformatics

View original post here:
MBT716 Lecture 6: Genome Browsers - Video

Tsunamaru - Daidai Genome [Insane] + Double Time
Another first try score :D.

By: GeeGee Bbybby

Read more:
Tsunamaru - Daidai Genome [Insane] + Double Time - Video

A quest to unravel the architecture of the double helix is revealing the subtle genetic orchestration of life

The genome packs into the nucleus in a manner consistent with the structure of a fractal globule, shown herea polymer state that is extraordinarily dense, but entirely unknotted. Credit: Olena Shmahalo/Quanta Magazine. Globule courtesy Miriam Huntley, Rob Scharein, and Erez Lieberman Aiden

FromQuanta Magazine(findoriginal story here).

The nuclei from a half-million human cells could all fit inside a single poppy seed. Yet within each and every nucleus resides genomic machinery that is incredibly vast, at least from a molecular point of view. It has billions of parts, many used to activate and silence genesan arrangementthat allows individual cells to specialize as brain cells, heart cells and some 200 other different cell types. Whats more, each cells genome is atwitter with millions of mobile pieces that swarm throughout the nucleus and latch on here and there to tweak the genetic program. Every so often, the genomic machinereplicates itself.

At the heart of the human genomes Lilliputian machinery is the two meters worth of DNA that it takes to embody a persons 3 billion genetic letters, or nucleotides. Stretch out all of the genomes in all of your bodys trillions of cells, saysTom Misteli, the head of the cell biology of genomes group at the National Cancer Institute in Bethesda, Md., and it would make 50 round trips to the sun. Since 1953, when James Watson and Francis Crick revealed the structure of DNA, researchers have made spectacular progress in spelling out these genetic letters. But this information-storage view reveals almost nothing about what makes specific genes turn on or off at different times, in different tissue types, at different moments in a persons day or life.

To figure out these processes, we must understand how those genetic letters collectively spiral about, coil, pinch off into loops, aggregate into domains and globules, and otherwise assume a nucleus-wide architecture. The beauty of DNA made people forget about the genomes larger-scale structure, saidJob Dekker, a molecular biologist at the University of Massachusetts Medical School in Worcester who has built some of the most consequential tools for unveiling genomic geometry. Now we are going back to studying the structure of the genome because we realize that the three-dimensional architecture of DNA will tell us how cells actually use the information. Everything in the genome only makes sense in 3-D.

Genome archaeologists like Dekker have invented and deployed molecular excavation techniques for uncovering the genomes architecture with the hope of finally discerning how all of that structure helps to orchestrate life on Earth. For the past decade or so, they have been exposing a nested hierarchy of structural motifs in genomes that are every bit as elemental to the identity and activity of each cell as the double helix.

A better genetic microscope A close investigation of the genomic machine has been a long time in coming. The early British microscopist Robert Hooke coined the wordcellas a result of his mid-17th-century observations of a thin section of cork. The small compartments he saw reminded him of monks living quarterstheir cells. By 1710, Antonie van Leeuwenhoek had spied tiny compartments within cells, though it was Robert Brown, of Brownian motion fame, who coined the wordnucleusto describe these compartments in the early 1830s. A half-century later, in 1888, the German anatomist Heinrich Wilhelm Gottfried von Waldeyer-Hartz peered through his microscope and decided to use the wordchromosomemeaning color bodyfor the tiny, dye-absorbing threads that he and others could see inside nuclei with the best microscopes of their day.

During the 20th century, biologists found that the DNA in chromosomes, rather than their protein components, is the molecular incarnation of genetic information. The sum total of the DNA contained in the 23 pairs of chromosomes is the genome. But how these chromosomes fit together largely remained a mystery.

Then in the early 1990s, Katherine Cullen and a team at Vanderbilt University developed a method to artificially fuse pieces of DNA that are nearby in the nucleusa seminal feat that made it possible to analyze the ultrafolded structure of DNA merely by reading the DNA sequence. This approach has been improved over the years. One of its latest iterations, calledHi-C, makes it possible to map the folding of entire genomes.

View post:
Human Genome's Spirals, Loops and Globules Come into 4-D View [Video]

PRESS RELEASE: Second Genome and Evotec to collaborate in microbiome discovery and development

DGAP-News: Evotec AG / Key word(s): Miscellaneous Second Genome and Evotec to collaborate in microbiome discovery and development

2015-03-13 / 07:31

=--------------------------------------------------------------------

Hamburg, Germany - 13 March 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec's integrated drug discovery platform.

As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are pleased to contribute to Second Genome's unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut. The enrichment and maturation of Second Genome's project portfolio through our contributions will enhance the Company's clinical pipeline in the near future."

Mohan Iyer, Chief Business Officer of Second Genome, added: "The partnership with Evotec allows us efficiently to translate our unique microbiome discovery platform efficiently into tangible drug molecules for clinical development. Our enriched pipeline offers new treatment approaches for patients across a wide range of diseases with an initial focus on inflammatory conditions. We look forward to a sustained partnership with Evotec."

Further financial terms were not disclosed.

ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.

Go here to see the original:
PRESS RELEASE: Second Genome and Evotec to collaborate in microbiome discovery and development

13.03.2015 / 07:31

---------------------------------------------------------------------

Hamburg, Germany - 13 March 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Second Genome, Inc. today announced a collaboration in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome's unique approach to identify and modulate microbiome-mediated pathways will be further enhanced by the use and the results of Evotec's integrated drug discovery platform.

As part of the collaboration, Second Genome and Evotec will work together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec's technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggers an undisclosed upfront payment. Evotec is also eligible for pre-clinical, clinical and regulatory milestones as well as royalty payments related to commercialisation.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are pleased to contribute to Second Genome's unique approach to treat microbiome-mediated diseases in the body with a particular emphasis on the gut. The enrichment and maturation of Second Genome's project portfolio through our contributions will enhance the Company's clinical pipeline in the near future."

Mohan Iyer, Chief Business Officer of Second Genome, added: "The partnership with Evotec allows us efficiently to translate our unique microbiome discovery platform efficiently into tangible drug molecules for clinical development. Our enriched pipeline offers new treatment approaches for patients across a wide range of diseases with an initial focus on inflammatory conditions. We look forward to a sustained partnership with Evotec."

Further financial terms were not disclosed.

ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to http://www.evotec.com.

ABOUT SECOND GENOME Second Genome's mission is to transform lives with medicines developed through innovative microbiome science. Second Genome has built a novel platform for microbiome drug discovery and is engaged in active programmes in multiple areas of significant unmet medical need Please visit http://www.secondgenome.com for more information.

FORWARD LOOKING STATEMENTS - Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

See the original post here:
DGAP-News: Second Genome and Evotec to collaborate in microbiome discovery and development

Sti Genome Exhaust Forester SH9
, .

By:

See more here:
Sti Genome Exhaust Forester SH9 - Video

Safra - Life
Summer Vibes! Massive EP coming from Safra! Definitely my favorite tune off the EP... This one #39;s out on Genome Records DOWNLOAD HERE: http://bit.do/Non-Real-EP -------------------------------...

By: Liquid Selection | Fresh, Liquid Drum Bass

Read this article:
Safra - Life - Video